



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No. 068430035	Serial No. 09/803,918
Applicant Jean-Michel DAYER et al.	RECEIVED
Filing Date March 13, 2001	Group: 1645 1644 FEB 28 2002

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Sub Class	Translation Yes or No	
Pnk	WO 96/37608	11/28/96	PCT			No (English Abstract)	
↓	WO 99/16409	04/08/99	PCT				
↓	WO 93/07165	04/15/93	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
Pnk	HAMIDI ASL et al.; A Novel Apolipoprotein A-1 Variant, Arg173Pro, Associated With Cardiac And Cutaneous Amyloidosis; Biochemical and Biophysical Research Communications 257, pp. 584-588 (1999).
↓	DAYER et al.; Apolipoprotein A-1 Inhibits IL-1 β And TNF- α Production by Blocking Contact-Mediated Activation Of Monocytes By T Lymphocytes; Arthritis and Rheumatism, 43, p. 1726 (2000).
↓	HYKA et al.; Apolipoprotein A-I inhibits the production of interleukin-1 β and tumor necrosis factor- α by blocking contact-mediated activation of monocytes by T lymphocytes; Blood, 97, pp. 2381-2389 (2001).

Examiner	Date Considered
<i>J. N. S.</i>	10/7/02

*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
------------	--

Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce
---------------	---

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.	06843.0035	Serial No.	09/803,918
Applicant	Jean-Michel DAYER, et al.		
Filing Date	March 13, 2001	Group:	1645 164f

U.S. PATENT DOCUMENTS


Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PSK	Bruhn, H., et al., "An Approach To The Functional Analysis Of Lecithin-Cholesterol Acyltransferase Activation By Recombinant Normal And Mutagenized Apolipoprotein AI," <i>Biol. Chem. Hoppe-Seyler</i> , 372:225-234, 1991. ✓
	McGuire, K. A., et al., "High Yield Overexpression And Characterization Of Human Recombinant Proapolipoprotein A-I," <i>J. Lipid Res.</i> , 37:1519-1528, 1996. ✓
	Moguilevsky, N., et al., "Production Of Authentic Human Proapolipoprotein A-I In Escherichia Coli: Strategies For The Removal Of The Amino-Terminal Methionine," <i>J. Biotechnol.</i> 27:159-172, 1993. ✓
	Moguilevsky, N., et al., "Production Of Human Recombinant Proapolipoprotein, A-I In Escherichia Coli : Purification And Biochemical Characterization," <i>DNA</i> 8:429-436, 1989.
	Pyle, L. E., et al., "Structural And Functional Properties Of Full-Length And Truncated Human Proapolipoprotein AI Expressed In Escherichia Coli," <i>Biochemistry</i> 35:12046-12052, 1996. ✓
✓	Sirtori, C. R., et al., "Recombinant Apolipoproteins For The Treatment Of Vascular Diseases," <i>Atherosclerosis</i> 142:29-40, 1999.

Examiner 	Date Considered Oct 7, 2002
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce